ZD6126
ZD6126
ZD6126 (/zɛd ˈsɪksˈtwɛnˈtwɛnɪ/) is a vasculature-disrupting agent that was developed by AstraZeneca for the treatment of solid tumors. It is a colchicine derivative that works by binding to the tubulin in the endothelial cells lining the blood vessels, causing them to collapse and cutting off the blood supply to the tumor.
Etymology
The term "ZD6126" is a code name given by AstraZeneca during the drug's development. The "ZD" prefix is commonly used by AstraZeneca for their investigational drugs, while the numbers "6126" do not have a known specific meaning.
Related Terms
- Vasculature: The arrangement of blood vessels in an organ or tissue.
- AstraZeneca: A British-Swedish multinational pharmaceutical and biopharmaceutical company.
- Tumor: An abnormal growth of tissue resulting from uncontrolled, progressive multiplication of cells and serving no physiological function.
- Colchicine: A medication most commonly used to treat gout.
- Tubulin: A protein that is the main constituent of the microtubules of living cells.
- Endothelial cells: Cells that line the interior surface of blood vessels and lymphatic vessels.
External links
- Medical encyclopedia article on ZD6126
- Wikipedia's article - ZD6126
This WikiMD article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski